



Aleta Biotherapeutics Announces Appointments to Board of Directors

Mark Leuchtenberger joins Board as Executive Chairman

Eva-Lotta Allan appointed as Non-Executive Director

NATICK, Mass., September 5, 2019 – [Aleta Biotherapeutics](#), a privately held immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, today announced the appointments of Mark Leuchtenberger as Executive Chairman and Eva-Lotta Allan as Non-Executive Director effective immediately.

Mark Leuchtenberger is an experienced life sciences executive, having held leadership roles at multiple companies. He is currently Interim Chief Executive Officer at Brooklyn ImmunoTherapeutics. Mr. Leuchtenberger has over 20 years of experience as a senior executive in the biopharmaceutical industry where he has led companies through successful private financings and initial public offerings, taken products from Investigational New Drug status through to commercialization, and has achieved M&A exits.

Eva-Lotta Allan has over 30 years of experience in the biopharmaceutical industry, most recently as Chief Business Officer at Immunocore, a clinical-stage T-cell receptor company. She has also served on a number of other Boards in both private and publicly held companies during her career. She is currently a Non-Executive Director for Targovax and Crescendo Biologics and is also Chairman of C4X Discovery.

“Mark and Eva-Lotta bring complementary skills to the Board of Aleta that are particularly important to us at this stage in our development,” said Paul Rennert, President, Co-Founder, and Chief Scientific Officer, Aleta Biotherapeutics. “Mark’s experience in leading companies from early clinical development through to commercial launch will support Aleta’s evolution as we move our lead program forward. Eva-Lotta’s corporate and strategic track record, significant business development achievements, and broad operational experiences in growing biotech companies will help Aleta as we expand the company and establish strategic alliances in the field of oncology. We are fortunate to have these seasoned executives on our Board as we explore the potential of our proprietary fusion proteins to attack and kill tumor cells.”

Mark Leuchtenberger and Eva-Lotta Allan join Roy Lobb, Co-Founder of Aleta Biotherapeutics, Raj Parekh, General Partner at Advent Life Sciences, and Paul Rennert on the Board of Directors.

“Aleta Biotherapeutics’ bridging protein strategy has the potential to address the most critical issues in cell therapy,” said Mark Leuchtenberger. “This unique approach offers the potential to confront antigen loss and tumor heterogeneity by targeting multiple antigens simultaneously with a single CD19-directed CAR. I am excited to be joining the Board and look forward to working with Paul Rennert and his team as they advance this new approach to cancer immunotherapy.”

Eva-Lotta Allan commented: “I am excited to join the Board of Aleta as the company is advancing to become a significant contributor to the immuno-oncology field based on its innovative approach to targeting tumors. Aleta is transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, including currently intractable solid tumors. I believe Aleta’s experienced management team is well positioned to successfully advance this exciting new approach to treating cancer.”

Mark Leuchtenberger

Mark Leuchtenberger, MBA has over 20 years of experience as a senior life sciences executive, during which he has led companies through multiple public and private financings and has advanced products from Investigational New Drug status through to commercialization. Previously, Mr. Leuchtenberger was President and Chief Executive Officer and a member of the Board of Directors at IRX Therapeutics, Chiasma (NASDAQ: CHMA), Acusphere, Inc., Rib-X Pharmaceuticals, Inc. (now Melinta Therapeutics, Inc.), Targanta Therapeutics Corporation, and Therion Biologics Corporation. Prior to Therion, Mr. Leuchtenberger was a senior officer at Biogen Inc., where he led the late-stage development of its flagship product Avonex and its commercialization in the United States and internationally in 65 countries. He is a Director and past Chairman of the Massachusetts Biotechnology Council Board of Directors and is a Co-Founder of Albor Biologics, Inc. and Alvos Therapeutics, Inc. Mr. Leuchtenberger received his MBA from the Yale School of Management and his BA from Wake Forest University.

Eva-Lotta Allan

Eva-Lotta Allan has more than 30 years of experience in the healthcare industry. During this time, she has been a senior executive and Board member at both public and private companies. Most recently, Eva-Lotta was Chief Business Officer (and previously a Board Member) at Immunocore, where she held full responsibility for all aspects of business development and played an instrumental role in the \$320 million fundraising in 2015. Prior to this, Eva-Lotta served as Chief Business Officer and member of the Executive Committee and Euronext IPO team for Ablynx NV, acquired in 2018 by Sanofi for EUR 3.9 billion.

Eva-Lotta also held senior positions at Vertex Pharmaceuticals (Europe) Ltd (now with a market capitalization of \$45.3 billion), Oxford Asymmetry International plc (now Evotec with a market capitalization of EUR 2.9 billion), Oxford Glycosciences (now part of UCB Celltech with a market capitalization of EUR 12.6 billion), and Amersham International (now part of GE Healthcare).

Eva-Lotta Allan currently serves as Non-Executive Director and Member of the Corporate Governance Committee and the R&D Sub-Committee of the Oslo listed company, Targovax ASA and is a Non-Executive Director of Crescendo Biologics and Chairman of C4X Discovery. Eva-Lotta was also a Board Member of the UK BiIndustry Association (BIA).

About Aleta Biotherapeutics

Aleta Biotherapeutics is an immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, including currently intractable solid tumors. The company was founded by Paul Rennert and Roy Lobb, who bring extensive scientific and leadership experience in immunology, oncology and drug development to this new enterprise. Aleta has created a unique portfolio of multi-antigen targeting solutions for cell therapy, designed to address the critical

issues of CAR-T persistence, tumor antigen loss leading to patient relapse, and tumor antigen heterogeneity. For more information, visit www.aletabio.com.

###

Media Contact:

Karen Sharma

MacDougall

781-235-3060

ksharma@macbiocom.com